Novavax Inc. (NASDAQ:NVAX)’s share price fell 4% on Tuesday . The company traded as low as $7.29 and last traded at $7.29, with a volume of 1,916,472 shares. The stock had previously closed at $7.59.

A number of brokerages recently weighed in on NVAX. Vetr raised shares of Novavax from a “buy” rating to a “strong-buy” rating and set a $8.35 price target on the stock in a report on Tuesday. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $14.00 price objective on shares of Novavax in a report on Wednesday, June 29th. Zacks Investment Research raised shares of Novavax from a “sell” rating to a “hold” rating in a report on Friday, June 10th. Finally, Wedbush reaffirmed an “outperform” rating and set a $14.00 price objective on shares of Novavax in a report on Thursday, June 2nd. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $12.21.

The stock has a 50 day moving average price of $6.96 and a 200 day moving average price of $5.74. The stock’s market cap is $2.02 billion.

Novavax (NASDAQ:NVAX) last released its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.27) by $0.02. The company earned $4.20 million during the quarter, compared to the consensus estimate of $10.39 million. During the same period last year, the firm earned ($0.10) EPS. The business’s quarterly revenue was down 57.6% compared to the same quarter last year. On average, analysts predict that Novavax Inc. will post ($0.96) EPS for the current year.

In related news, Director Gary C. Evans sold 50,000 shares of Novavax stock in a transaction dated Tuesday, May 24th. The stock was sold at an average price of $5.41, for a total value of $270,500.00. Following the completion of the sale, the director now directly owns 357,111 shares in the company, valued at approximately $1,931,970.51. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Gary C. Evans sold 18,998 shares of Novavax stock in a transaction dated Monday, June 6th. The stock was sold at an average price of $6.50, for a total value of $123,487.00. Following the completion of the sale, the director now owns 321,979 shares of the company’s stock, valued at $2,092,863.50. The disclosure for this sale can be found here.

Other large investors have added to or reduced their stakes in the company. ProShare Advisors LLC increased its stake in Novavax by 10.4% in the fourth quarter. ProShare Advisors LLC now owns 266,138 shares of the biopharmaceutical company’s stock valued at $2,233,000 after buying an additional 25,114 shares during the last quarter. Rhumbline Advisers increased its stake in Novavax by 12.6% in the fourth quarter. Rhumbline Advisers now owns 271,881 shares of the biopharmaceutical company’s stock valued at $2,281,000 after buying an additional 30,395 shares during the last quarter. Tekla Capital Management LLC acquired a new stake in Novavax during the fourth quarter valued at approximately $3,004,000. California State Teachers Retirement System increased its stake in Novavax by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 496,682 shares of the biopharmaceutical company’s stock valued at $4,167,000 after buying an additional 7,860 shares during the last quarter. Finally, TD Asset Management Inc. increased its stake in Novavax by 7.5% in the fourth quarter. TD Asset Management Inc. now owns 576,800 shares of the biopharmaceutical company’s stock valued at $4,839,000 after buying an additional 40,000 shares during the last quarter.

Novavax, Inc (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.